5-(Aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide and its use in medicine
申请人:Morvus Technology Ltd.
公开号:EP2258430A2
公开(公告)日:2010-12-08
There is provided 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide for various uses, as well as pharmaceutical compositions and devices comprising 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide. There is also provided a method for reducing reducible compounds (such as reduction-activated prodrugs, e.g. tretazicar) by contacting those compounds with α-hydroxycarbonyl compounds capable of forming cyclic dimers.
Use of alpha-hydroxy carbonyl compounds as reducing agents
申请人:Morvus Technology Ltd
公开号:US10398676B2
公开(公告)日:2019-09-03
There is provided the use as reducing agents of alpha-hydroxycarbonyl compounds capable of forming cyclic dimers. There is also provided corresponding methods of reducing reducible compounds, particularly reduction-activated prodrugs. Examples of the alpha-hydroxycarbonyl compounds used are dihydroxyacetone, glycolaldehyde, glyceraldehyde, erythrose, xylulose, erythrulose or 3-hydroxy-2-butanone.